Best Peptides for Weight Loss and Fat Loss (2026)
GLP-1 peptides broke the internet and rewired medicine in the process. Six compounds ranked by evidence, not by who sells them: what the clinical data says, how to dose them, and what the side effects feel like.
Three of the weight loss peptides on this list are FDA-approved. One posted the highest weight loss numbers ever recorded in a clinical trial. One failed its human trial in 2007 and people still buy it. This page exists so you can tell the difference.
Do not start a GLP-1 if you have a personal or family history of medullary thyroid carcinoma or MEN2, are pregnant or trying to conceive, have a history of pancreatitis, or have gastroparesis. The disqualifiers in full →
How to choose the right weight loss peptide
What you are signing up for
Data says: yes, most people regain about two-thirds of the weight within a year of stopping. The STEP 1 extension trial showed this clearly. GLP-1 peptides are not a course of treatment you complete. They work while you take them. Stopping means the appetite suppression stops. This is a long-term commitment, not a 12-week fix. Factor that into your decision.
The 6 best peptides for weight loss, ranked
You want the biggest result available now and can ride out the nausea while you titrate.
You cannot get a prescription, or you need to avoid GI side effects entirely.
Why this one
Dual GLP-1/GIP receptor agonist. Beat semaglutide head-to-head in the SURMOUNT trials with approximately 22.5% body weight loss at the highest dose (Jastreboff et al., NEJM 2023).
Dosing and side effects
You want the largest safety dataset, or you carry cardiovascular risk alongside the weight.
You want the biggest number on the page. Tirzepatide beat it head to head.
Why this one
The one that started the GLP-1 weight loss conversation, and the most studied compound on this list. The STEP trials showed approximately 15% body weight loss at the 2.4 mg dose (Wilding et al., NEJM 2021). The SELECT trial also showed a 20% reduction in major cardiovascular events in overweight adults (Lincoff et al., NEJM 2023).
Dosing and side effects
You are deciding what to plan for rather than what to start this month.
You want to start now. There is no prescription and no compounding route.
Why this one
Triple agonist: GLP-1, GIP, and glucagon. Phase 2 posted 24.2% body weight loss at 48 weeks at the highest dose (Jastreboff et al., NEJM 2023). That is higher than any approved drug has achieved.
Dosing and side effects
Deep belly fat is the concern and a daily injection is acceptable.
You want total body weight down. The scale may barely move.
Why this one
Not a GLP-1. A growth hormone-releasing hormone analog that targets visceral fat specifically, the deep belly fat wrapping your organs. MRI scan data confirmed visceral adipose tissue reduction in large trials. The scale might not move much, but the body composition does.
Dosing and side effects
You have weight and liver concerns and you are planning ahead.
You want to start now. Still in trials.
Why this one
Dual GLP-1 and glucagon receptor agonist. Phase 3 results: 16.6% body weight loss, plus impressive liver fat reduction data. Notable because it also targets non-alcoholic fatty liver disease (NAFLD).
Dosing and side effects
Nothing on this page recommends it. It is here because people search for it.
You want weight loss. The Phase 2b trial missed its primary endpoint.
Why this one
A growth hormone fragment (amino acids 176-191) that was supposed to be a fat burner. The animal data on lipolysis looked promising. The Phase 2b human trial in 536 obese adults failed its primary endpoint for weight loss at 24 weeks. GLP-1 peptides exist now. The evidence gap is not close.
Dosing and side effects
Cost is shown only where this page sources it.
Who should not use GLP-1 peptides
Peptide injections for weight loss: how they work
All the weight loss peptides on this list are injected subcutaneously. A small insulin needle (29-31 gauge) into belly or thigh fat, once a week for the GLP-1s, once daily for tesamorelin. Branded pens (Ozempic, Mounjaro) come pre-filled. Compounded versions come in vials that you reconstitute with bacteriostatic water. The peptide calculator tells you exactly how much to draw. Never done it before? The start here guide walks you through your first injection in four minutes. Peptide therapy for weight loss is the same injection process as insulin. If diabetics can do it daily, you can do it weekly.
Compounded vs brand-name GLP-1 peptides
Same active molecule, different packaging. Branded pens are manufactured by Novo Nordisk (semaglutide) or Eli Lilly (tirzepatide) under FDA oversight; compounded versions are made by compounding pharmacies against a prescription. The trade-off is convenience against cost: pens dial and click, vials cost 5-8x less but you mix and measure yourself. You will need injection supplies (syringes, BAC water, alcohol pads). If you are sourcing compounded vials, vet your supplier first. See the full pen vs vial comparison.
Insulin syringes (29-31 gauge), bacteriostatic water, alcohol pads, a sharps container and somewhere cold to keep the vial. See the prep kit.
What to expect: dose escalation timeline
Appetite starts to shift. Most people notice they forget to eat or feel full faster. Weight loss is modest, 1-2 lbs. Nausea is most likely in this window.
If nausea stops you eating or drinking, do not move up. Hold the starting dose another four weeks.
Each dose increase restarts the nausea cycle for a few days. Weight loss accelerates. Most people see 5-8% body weight loss by week 12 on semaglutide, faster on tirzepatide.
If a dose increase floors you for more than a week, step back down one level and stay there. Slower titration reaches the same maintenance dose.
Weight loss continues but the rate slows. This is normal. The curve flattens as you approach your body's new setpoint. Most of the headline trial numbers (15%, 22%) are measured at 68-72 weeks.
If the scale has not moved in six weeks at a full dose, check protein and training before assuming the drug failed. Then ask about switching.
You are on maintenance. The weight stays off while you stay on the peptide. If you stop, expect regain. The SURMOUNT-4 trial showed participants who switched from tirzepatide to placebo regained about 14% of their body weight over the following year.
If you need to come off, taper rather than stop dead, and have the food and training habits running first.
Peptides are not a shortcut. Lifestyle still matters.
Every GLP-1 trial includes "standard lifestyle counseling" as part of the protocol. The 15-24% weight loss numbers assume you are also eating less, moving more, and sleeping. The peptide suppresses your appetite; it does not make your food choices for you.
- Hit 1.2-1.6g of protein per kg of body weight, every day. You are eating less overall, and the shortfall comes out of muscle.
- Lift twice a week, three if you can. Resistance training is what keeps the ~27% of loss that is lean mass from growing.
- Drink more than feels necessary. Reduced intake means reduced fluid, and dehydration reads as nausea.
- Weigh weekly, not daily, and photograph monthly. The scale under-reports what is happening to body composition.
How do peptides help you lose weight?
Your gut makes a hormone called GLP-1 after you eat. It tells your brain you are full, slows your stomach from emptying, and makes your cells better at using insulin. GLP-1 peptides are lab-made versions of that signal, cranked up way past what your body would produce on its own. Your appetite drops. Your stomach takes longer to empty. You eat less without white-knuckling it. That is why GLP-1 weight loss works.
Some fat loss peptides hit more than one receptor. Tirzepatide adds GIP (a second gut hormone that helps with insulin and appetite). Retatrutide adds GIP and glucagon (which also mobilizes fat stores). More receptors has meant more weight loss in every trial so far. Tesamorelin is a different animal entirely: it triggers growth hormone release, which specifically targets the deep visceral fat around your organs.
One thing the trials show that people do not talk about enough: roughly 73% of the weight lost on GLP-1s is fat mass, not lean mass. You will lose some muscle. The higher the dose and the faster the loss, the more muscle goes with it. Resistance training and adequate protein intake (1.2-1.6g per kg of body weight) during treatment are not optional if you care about body composition, not just the number on the scale.
Do peptides work for weight loss?
The GLP-1 peptides on this list have the strongest clinical trial data in all of peptide medicine. Semaglutide and tirzepatide are not fringe. They are FDA-approved, prescribed by primary care doctors, and studied in trials with tens of thousands of participants. The question is not "do peptides work for weight loss" but "which GLP-1 peptide fits your situation."
How much weight can you lose on peptides?
Clinical trial averages: semaglutide ~15% of body weight, tirzepatide ~22.5%, retatrutide ~24.2% (Phase 2). Individual results vary. These numbers are from trial populations using the drugs as prescribed with standard lifestyle counseling. Some people lose more, some less. The weight loss is real and statistically significant across every major trial.
Frequently asked questions about peptides for weight loss
Tirzepatide has better weight loss numbers in head-to-head trials. Semaglutide has a larger safety dataset and more prescribing history. If your insurance covers one and not the other, that may decide it. If you are paying out of pocket with compounded peptides, tirzepatide at equivalent doses produces more weight loss. See the full semaglutide vs tirzepatide comparison.
It hits up to 44% of people and it is the number one reason people quit. It is worst in the first 2-4 weeks and during dose increases. Most people's nausea fades as their body adjusts. Eat smaller meals, avoid greasy food, stay hydrated, and do not skip the titration schedule. Full nausea management guide. Some clinics stack BPC-157 for gut protection alongside GLP-1s. See the full side effects FAQ.
By the data: tirzepatide. It hit 22.5% weight loss in SURMOUNT vs 15% for semaglutide in STEP. Retatrutide posted 24.2% in Phase 2 but is not yet available. Among approved options, tirzepatide for weight loss has the strongest numbers.
No. AOD-9604 failed its Phase 2b human trial in 2007 for weight loss. The development was discontinued. GLP-1 peptides (semaglutide, tirzepatide) have massive trial data proving efficacy. A peptide fat burner that failed its trial is not comparable to FDA-approved compounds that consistently produce 15-24% weight loss.
GLP-1 peptides reduce total body fat, including visceral belly fat. Tesamorelin specifically targets visceral adipose tissue and is FDA-approved for that indication. If your concern is the deep fat wrapping your organs (not just subcutaneous belly fat), tesamorelin has the most direct evidence.
No interaction is listed, but alcohol lands harder when your stomach empties slowly and you are eating less. Lower tolerance and worse nausea are the two things people report most. It also adds calories the appetite suppression is working against.
Under five days late: take it when you remember and keep your usual weekly day. Longer than that: skip it and resume on schedule. Never double up. If you miss two weeks or more, expect to step back down the titration ladder rather than restarting at your old dose.
Tirzepatide can reduce the absorption of oral contraceptives, most likely around a dose increase. Lilly advises a barrier method or a non-oral contraceptive for four weeks after starting and after each dose increase. Semaglutide carries no comparable warning.
There is no documented interaction, and the two are frequently prescribed together. Both can cause nausea, so the first weeks may be rougher than either alone. Anything involving mood changes belongs with your prescriber, not a forum.
Related comparisons
Where to go from here
÷ Open the peptide calculator Vial strength, water, dose. It prints the units on the syringe.Also: every question · storage guide · something feels off?
Content reviewed against PubMed, ClinicalTrials.gov, and FDA databases. Evidence tiers assigned using the vialprep methodology. Last reviewed September 2026. This content is not medical advice. Talk to a licensed clinician before starting any weight loss protocol.